speb/financial-data huggingface dataset:
BIOX balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 295218562.00
BIOX income_statement (annual, 2025-06-30) — Total Expenses: 334105891.00
BIOX income_statement (quarterly, 2025-06-30) — Total Expenses: 81283959.00
BIOX balance_sheet (annual, 2025-06-30) — Total Liabilities Net Minority Interest: 468426518.00
BIOX balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 468426518.00
BIOX balance_sheet (annual, 2025-06-30) — Total Non Current Assets: 455333583.00
BIOX balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 455333583.00
BIOX balance_sheet (annual, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 130440547.00
BIOX balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 130440547.00
BIOX income_statement (annual, 2025-06-30) — Total Operating Income As Reported: -2235962.00
BIOX income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -13456410.00
BIOX income_statement (annual, 2025-06-30) — Total Other Finance Cost: 8078954.00
BIOX income_statement (quarterly, 2025-06-30) — Total Other Finance Cost: 5879252.00
BIOX balance_sheet (annual, 2025-06-30) — Total Tax Payable: 3736656.00
BIOX balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 3736656.00
BIOX income_statement (annual, 2025-06-30) — Total Unusual Items: -20999241.00
BIOX income_statement (quarterly, 2025-06-30) — Total Unusual Items: -23668710.00
BIOX income_statement (annual, 2025-06-30) — Total Unusual Items Excluding Goodwill: -20999241.00
BIOX income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -23668710.00
BIOX balance_sheet (annual, 2025-06-30) — Tradeand Other Payables Non Current: 48481726.00
BIOX balance_sheet (quarterly, 2025-06-30) — Tradeand Other Payables Non Current: 48481726.00
BIOX balance_sheet (annual, 2025-06-30) — Treasury Shares Number: 2402692.00
BIOX balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 2402692.00
BIOX balance_sheet (annual, 2025-06-30) — Treasury Stock: 32214878.00
BIOX balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 32214878.00
BIOX balance_sheet (annual, 2025-06-30) — Working Capital: -29674474.00
BIOX balance_sheet (quarterly, 2025-06-30) — Working Capital: -29674474.00
BIOX income_statement (annual, 2025-06-30) — Write Off: 7123716.00
BIOX income_statement (quarterly, 2025-06-30) — Write Off: 5273880.00
BIOX income_statement (quarterly, 2025-09-30) — +Operating Expense: 27882913.00
BIOX income_statement (quarterly, 2025-09-30) — +Total Revenue: 77435995.00
BIOX balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 89807917.00
BIOX balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 158385229.00
BIOX balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -14844227.00
BIOX balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 326359232.00
BIOX balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -15806199.00
BIOX income_statement (quarterly, 2025-09-30) — Amortization: 1372964.00
BIOX cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 3248270.00
BIOX cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 3248270.00
BIOX income_statement (quarterly, 2025-09-30) — Amortization Of Intangibles Income Statement: 1372964.00
BIOX balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 52.00
BIOX income_statement (quarterly, 2025-09-30) — Basic Average Shares: 63428167.00
BIOX income_statement (quarterly, 2025-09-30) — Basic EPS: -0.12
BIOX cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 32695079.00
BIOX cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -1370626.00
BIOX cash_flow (quarterly, 2025-09-30) — Capital Expenditure Reported: -668297.00
BIOX balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 15913114.00
BIOX balance_sheet (quarterly, 2025-09-30) — Capital Stock: 6500.00
BIOX balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 15505146.00
BIOX balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 16612427.00
BIOX cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: 0.00
BIOX balance_sheet (quarterly, 2025-09-30) — Cash Equivalents: 3776940.00
BIOX balance_sheet (quarterly, 2025-09-30) — Cash Financial: 11728206.00
BIOX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -28710084.00
BIOX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -1264065.00
BIOX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 14376987.00
BIOX cash_flow (quarterly, 2025-09-30) — Change In Inventory: -451257.00
BIOX cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -3885102.00
BIOX cash_flow (quarterly, 2025-09-30) — Change In Payable: -2873750.00
BIOX cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: -2873750.00
BIOX cash_flow (quarterly, 2025-09-30) — Change In Receivables: 4318198.00
BIOX cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -2891911.00
BIOX cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 5400597.00
BIOX cash_flow (quarterly, 2025-09-30) — Changes In Cash: -15597162.00
BIOX balance_sheet (quarterly, 2025-09-30) — Common Stock: 6500.00
BIOX balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 256029577.00
BIOX balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 17186369.00
BIOX income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 41791598.00
BIOX balance_sheet (quarterly, 2025-09-30) — Current Assets: 283150286.00
BIOX balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 3146267.00
BIOX balance_sheet (quarterly, 2025-09-30) — Current Debt: 188737632.00
BIOX balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 191883899.00
BIOX balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 2322877.00
BIOX balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 2322877.00
BIOX balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 299715064.00
BIOX balance_sheet (quarterly, 2025-09-30) — Current Notes Payable: 103600000.00
BIOX cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: 2082995.00
BIOX cash_flow (quarterly, 2025-09-30) — Deferred Tax: 2082995.00
BIOX cash_flow (quarterly, 2025-09-30) — Depreciation: 2583430.00
BIOX cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 5831700.00
BIOX income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 2565424.00
BIOX cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 5831700.00
BIOX income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 2565424.00
BIOX income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 1192460.00
BIOX income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 63428167.00
BIOX income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.12
BIOX income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -7327885.00
BIOX balance_sheet (quarterly, 2025-09-30) — Duefrom Related Parties Current: 278738.00
BIOX balance_sheet (quarterly, 2025-09-30) — Duefrom Related Parties Non Current: 22125389.00
BIOX balance_sheet (quarterly, 2025-09-30) — Dueto Related Parties Current: 116416.00
BIOX balance_sheet (quarterly, 2025-09-30) — Dueto Related Parties Non Current: 765576.00
BIOX income_statement (quarterly, 2025-09-30) — EBIT: 3184715.00
BIOX income_statement (quarterly, 2025-09-30) — EBITDA: 9016415.00
BIOX income_statement (quarterly, 2025-09-30) — Earnings From Equity Interest: 296772.00
BIOX cash_flow (quarterly, 2025-09-30) — Earnings Losses From Equity Investments: -296772.00
BIOX cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -1592727.00
BIOX cash_flow (quarterly, 2025-09-30) — End Cash Position: 15505146.00
BIOX cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -28710084.00
BIOX balance_sheet (quarterly, 2025-09-30) — Finished Goods: 73092793.00
BIOX balance_sheet (quarterly, 2025-09-30) — Fixed Assets Revaluation Reserve: -160702.00
BIOX balance_sheet (quarterly, 2025-09-30) — Foreign Currency Translation Adjustments: -70038.00
BIOX cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 13006361.00
BIOX cash_flow (quarterly, 2025-09-30) — Gain Loss On Sale Of PPE: 2602.00
BIOX income_statement (quarterly, 2025-09-30) — Gain On Sale Of Ppe: 0.00
BIOX income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: -820388.00
BIOX balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -230740.00
BIOX income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 14315696.00
BIOX balance_sheet (quarterly, 2025-09-30) — Goodwill: 112163432.00
BIOX balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 290805262.00
BIOX balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 174191428.00
BIOX balance_sheet (quarterly, 2025-09-30) — Gross PPE: 104674615.00
BIOX income_statement (quarterly, 2025-09-30) — Gross Profit: 35644397.00
BIOX balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 3019472.00
BIOX income_statement (quarterly, 2025-09-30) — Insurance And Claims: 804730.00
BIOX income_statement (quarterly, 2025-09-30) — Interest Expense: 8549952.00
BIOX income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 8549952.00
BIOX cash_flow (quarterly, 2025-09-30) — Interest Paid Cff: -3854103.00
BIOX cash_flow (quarterly, 2025-09-30) — Interest Received Cfo: 2555154.00
BIOX balance_sheet (quarterly, 2025-09-30) — Inventories Adjustments Allowances: -3680270.00
BIOX balance_sheet (quarterly, 2025-09-30) — Inventory: 89804100.00
BIOX balance_sheet (quarterly, 2025-09-30) — Invested Capital: 498569241.00
BIOX cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -1264065.00
BIOX balance_sheet (quarterly, 2025-09-30) — Investment Properties: 569500.00
BIOX balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 52.00
BIOX balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 39425986.00
BIOX cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: 11845324.00
BIOX balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 12766847.00
BIOX balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 53802032.00
BIOX balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 66568879.00
BIOX cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: 11845324.00
BIOX cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -36134854.00
BIOX balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 39425934.00
BIOX balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 1163251.00
BIOX balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 17972438.00
BIOX balance_sheet (quarterly, 2025-09-30) — Minority Interest: 32299353.00
BIOX income_statement (quarterly, 2025-09-30) — Minority Interests: 120347.00
BIOX balance_sheet (quarterly, 2025-09-30) — Net Debt: 227034518.00
BIOX income_statement (quarterly, 2025-09-30) — Net Income: -7327885.00
BIOX income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -7327885.00
BIOX income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -7448232.00
BIOX income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -7327885.00
BIOX income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -7327885.00
BIOX cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -7448232.00
BIOX income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -7448232.00
BIOX cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -30214.00
BIOX income_statement (quarterly, 2025-09-30) — Net Interest Income: -11752395.00
BIOX cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 106561.00
BIOX cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -24289530.00
BIOX cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -24289530.00
BIOX income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -11752395.00
BIOX cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -566451.00
BIOX balance_sheet (quarterly, 2025-09-30) — Net PPE: 89830388.00
BIOX cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -672115.00
BIOX balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -34775685.00
BIOX balance_sheet (quarterly, 2025-09-30) — Non Current Accounts Receivable: 25445182.00
BIOX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 5421463.00
BIOX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 30111072.00
BIOX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 1835787.00
BIOX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 5421463.00
BIOX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 28275285.00
BIOX balance_sheet (quarterly, 2025-09-30) — Non Current Note Receivables: 230000.00
BIOX income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 10491837.00
BIOX income_statement (quarterly, 2025-09-30) — Normalized Income: -6368860.70
BIOX cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 14376987.00
BIOX cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -294170.00
BIOX income_statement (quarterly, 2025-09-30) — Operating Income: 7761484.00
BIOX income_statement (quarterly, 2025-09-30) — Operating Revenue: 77435995.00
BIOX balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 63478813.00
BIOX cash_flow (quarterly, 2025-09-30) — Other Cash Adjustment Outside Changein Cash: -44.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 100000.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 188737632.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 815202.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 30749501.00
BIOX income_statement (quarterly, 2025-09-30) — Other Gand A: 4602075.00
BIOX income_statement (quarterly, 2025-09-30) — Other Income Expense: -1374326.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 178641830.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Inventories: 1211504.00
BIOX cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 13395159.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 200000.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 355981.00
BIOX income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -195676.00
BIOX income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 658015.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Payable: 1434858.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Properties: 30631571.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Receivables: 1386307.00
BIOX balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 1107281.00
BIOX income_statement (quarterly, 2025-09-30) — Other Taxes: 2398466.00
BIOX balance_sheet (quarterly, 2025-09-30) — Payables: 99169063.00
BIOX balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 99169063.00
BIOX balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 5524023.00
BIOX balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 6025332.00
BIOX income_statement (quarterly, 2025-09-30) — Pretax Income: -5365237.00
BIOX balance_sheet (quarterly, 2025-09-30) — Properties: 38884237.00
BIOX cash_flow (quarterly, 2025-09-30) — Provisionand Write Offof Assets: 1145759.00
BIOX cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -30214.00
BIOX cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -53983.00
BIOX cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -672115.00
BIOX balance_sheet (quarterly, 2025-09-30) — Raw Materials: 19180073.00
BIOX balance_sheet (quarterly, 2025-09-30) — Receivables: 170708427.00
BIOX income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 38525322.00
BIOX income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 5831700.00
BIOX cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -36134854.00
BIOX income_statement (quarterly, 2025-09-30) — Research And Development: 5716468.00
BIOX balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -72371268.00
BIOX income_statement (quarterly, 2025-09-30) — Salaries And Wages: 8908891.00
BIOX cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 160544.00
BIOX cash_flow (quarterly, 2025-09-30) — Sale Of PPE: 0.00
BIOX income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 2228844.00
BIOX income_statement (quarterly, 2025-09-30) — Selling General And Administration: 16544540.00
BIOX balance_sheet (quarterly, 2025-09-30) — Share Issued: 65644451.00
BIOX income_statement (quarterly, 2025-09-30) — Special Income Charges: -655034.00
BIOX cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 533.00
BIOX balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 256029577.00
BIOX balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -34775685.00
BIOX income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -516397.70
BIOX income_statement (quarterly, 2025-09-30) — Tax Provision: 2082995.00
BIOX income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.35
BIOX balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 10658153.00
BIOX balance_sheet (quarterly, 2025-09-30) — Total Assets: 734878067.00
BIOX balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 309831609.00
BIOX balance_sheet (quarterly, 2025-09-30) — Total Debt: 258452778.00
BIOX balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 288328930.00
BIOX income_statement (quarterly, 2025-09-30) — Total Expenses: 69674511.00
BIOX balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 446549137.00
BIOX balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 451727781.00
BIOX balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 146834073.00
BIOX income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 7207546.00
BIOX income_statement (quarterly, 2025-09-30) — Total Other Finance Cost: 3202443.00
BIOX balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 7809872.00
BIOX income_statement (quarterly, 2025-09-30) — Total Unusual Items: -1475422.00
BIOX income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -1475422.00
BIOX balance_sheet (quarterly, 2025-09-30) — Tradeand Other Payables Non Current: 47869314.00
BIOX balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 2165638.00
BIOX balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 28483648.00
BIOX balance_sheet (quarterly, 2025-09-30) — Working Capital: -16564778.00
BIOX income_statement (quarterly, 2025-09-30) — Write Off: 655034.00
BIOX income_statement (quarterly, 2025-12-31) — +Operating Expense: 18488086.00
BIOX income_statement (quarterly, 2025-12-31) — +Total Revenue: 73674526.00
BIOX balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 82536392.00
BIOX balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 154931523.00
BIOX balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -12605994.00
BIOX balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 323534140.00
BIOX balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -16351856.00
BIOX income_statement (quarterly, 2025-12-31) — Amortization: 399563.00
BIOX cash_flow (quarterly, 2025-12-31) — Amortization Cash Flow: -217875.00
BIOX cash_flow (quarterly, 2025-12-31) — Amortization Of Intangibles: -217875.00
BIOX income_statement (quarterly, 2025-12-31) — Amortization Of Intangibles Income Statement: 399563.00
BIOX balance_sheet (quarterly, 2025-12-31) — Assets Held For Sale Current: 42363563.00
BIOX income_statement (quarterly, 2025-12-31) — Basic Average Shares: 63477113.00
BIOX income_statement (quarterly, 2025-12-31) — Basic EPS: -2.88
BIOX cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 15505146.00
BIOX cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -216107.00
BIOX cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -226177.00
BIOX balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 10883102.00
BIOX balance_sheet (quarterly, 2025-12-31) — Capital Stock: 6500.00
BIOX balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 11064683.00
BIOX balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 12579828.00
BIOX cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: 0.00
BIOX balance_sheet (quarterly, 2025-12-31) — Cash Equivalents: 1891524.00
BIOX balance_sheet (quarterly, 2025-12-31) — Cash Financial: 9173159.00
BIOX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -16926029.00
BIOX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -727712.00
BIOX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 23093852.00
BIOX cash_flow (quarterly, 2025-12-31) — Change In Inventory: 13090962.00
BIOX cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 1671274.00
BIOX cash_flow (quarterly, 2025-12-31) — Change In Payable: 8605584.00
BIOX cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 8605584.00
BIOX cash_flow (quarterly, 2025-12-31) — Change In Receivables: -14394369.00
BIOX cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 8973451.00
BIOX cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -12227654.00
BIOX cash_flow (quarterly, 2025-12-31) — Changes In Cash: -3407609.00
BIOX balance_sheet (quarterly, 2025-12-31) — Common Stock: 6500.00
BIOX balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 73770442.00
BIOX balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 16057841.00
BIOX income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 47361893.00
BIOX balance_sheet (quarterly, 2025-12-31) — Current Assets: 294280054.00
BIOX balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 2765072.00
BIOX balance_sheet (quarterly, 2025-12-31) — Current Debt: 194417397.00
BIOX balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 197182469.00
BIOX balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 2497944.00
BIOX balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 2497944.00
BIOX balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 328636804.00
BIOX balance_sheet (quarterly, 2025-12-31) — Current Notes Payable: 104354169.00
BIOX cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: 3505399.00
BIOX cash_flow (quarterly, 2025-12-31) — Deferred Tax: 3505399.00
BIOX cash_flow (quarterly, 2025-12-31) — Depreciation: 1403580.00
BIOX cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 1185705.00
BIOX income_statement (quarterly, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 962523.00
BIOX cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 1185705.00
BIOX income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 962523.00
BIOX income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 562960.00
BIOX income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 63477113.00
BIOX income_statement (quarterly, 2025-12-31) — Diluted EPS: -2.88
BIOX income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -183039821.00
BIOX balance_sheet (quarterly, 2025-12-31) — Duefrom Related Parties Current: 279854.00
BIOX balance_sheet (quarterly, 2025-12-31) — Duefrom Related Parties Non Current: 22389852.00
BIOX balance_sheet (quarterly, 2025-12-31) — Dueto Related Parties Current: 805903.00
BIOX balance_sheet (quarterly, 2025-12-31) — Dueto Related Parties Non Current: 742301.00
BIOX income_statement (quarterly, 2025-12-31) — EBIT: 5654825.00
BIOX income_statement (quarterly, 2025-12-31) — EBITDA: 6840530.00
BIOX income_statement (quarterly, 2025-12-31) — Earnings From Equity Interest: 72254.00
BIOX cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: -72254.00
BIOX cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -476995.00
BIOX cash_flow (quarterly, 2025-12-31) — End Cash Position: 11064683.00
BIOX cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -17992358.00
BIOX balance_sheet (quarterly, 2025-12-31) — Finished Goods: 51526125.00
BIOX balance_sheet (quarterly, 2025-12-31) — Fixed Assets Revaluation Reserve: -160702.00
BIOX balance_sheet (quarterly, 2025-12-31) — Foreign Currency Translation Adjustments: 222355.00
BIOX cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 17172794.00
BIOX cash_flow (quarterly, 2025-12-31) — Gain Loss On Sale Of PPE: -26504.00
BIOX income_statement (quarterly, 2025-12-31) — Gain On Sale Of Ppe: 26504.00
BIOX income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -938299.00
BIOX balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 61653.00
BIOX income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 9739212.00
BIOX balance_sheet (quarterly, 2025-12-31) — Goodwill: 36073683.00
BIOX balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 123363484.00
BIOX balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 171283379.00
BIOX balance_sheet (quarterly, 2025-12-31) — Gross PPE: 84667225.00
BIOX income_statement (quarterly, 2025-12-31) — Gross Profit: 26312633.00
BIOX balance_sheet (quarterly, 2025-12-31) — Income Tax Payable: 6428697.00
BIOX income_statement (quarterly, 2025-12-31) — Insurance And Claims: 365576.00
BIOX income_statement (quarterly, 2025-12-31) — Interest Expense: 7020963.00
BIOX income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 7020963.00
BIOX cash_flow (quarterly, 2025-12-31) — Interest Paid Cff: -3128842.00
BIOX cash_flow (quarterly, 2025-12-31) — Interest Received Cfo: 1570506.00
BIOX balance_sheet (quarterly, 2025-12-31) — Inventories Adjustments Allowances: -3320292.00
BIOX balance_sheet (quarterly, 2025-12-31) — Inventory: 67153113.00
BIOX balance_sheet (quarterly, 2025-12-31) — Invested Capital: 302343802.00
BIOX cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -2804152.00
BIOX balance_sheet (quarterly, 2025-12-31) — Investment Properties: 0.00
BIOX balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 39474962.00
BIOX cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 5167134.00
BIOX balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 8118030.00
BIOX balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 34155963.00
BIOX balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 42273993.00
BIOX cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 5167134.00
BIOX cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -18507567.00
BIOX balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 39474913.00
BIOX balance_sheet (quarterly, 2025-12-31) — Long Term Provisions: 1238122.00
BIOX balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 10430757.00
BIOX balance_sheet (quarterly, 2025-12-31) — Minority Interest: 32845859.00
BIOX income_statement (quarterly, 2025-12-31) — Minority Interests: -570290.00
BIOX balance_sheet (quarterly, 2025-12-31) — Net Debt: 217508677.00
BIOX income_statement (quarterly, 2025-12-31) — Net Income: -183039821.00
BIOX income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -183039821.00
BIOX income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -4475508.00
BIOX income_statement (quarterly, 2025-12-31) — Net Income Discontinuous Operations: -177994023.00
BIOX income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -183039821.00
BIOX income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -5045798.00
BIOX cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -1767658.00
BIOX income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -182469531.00
BIOX cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: -2403.00
BIOX income_statement (quarterly, 2025-12-31) — Net Interest Income: -7950232.00
BIOX cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -538109.00
BIOX cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -13340433.00
BIOX cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -13340433.00
BIOX income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -7950232.00
BIOX cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -945047.00
BIOX balance_sheet (quarterly, 2025-12-31) — Net PPE: 72061231.00
BIOX cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: 38977.00
BIOX balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: -49593042.00
BIOX balance_sheet (quarterly, 2025-12-31) — Non Current Accounts Receivable: 25430859.00
BIOX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 5520951.00
BIOX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 28830705.00
BIOX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 1436912.00
BIOX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 5520951.00
BIOX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 27393793.00
BIOX balance_sheet (quarterly, 2025-12-31) — Non Current Note Receivables: 230000.00
BIOX income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 8179647.00
BIOX income_statement (quarterly, 2025-12-31) — Normalized Income: -4175371.95
BIOX cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 17388901.00
BIOX cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -98758.00
BIOX income_statement (quarterly, 2025-12-31) — Operating Income: 7824547.00
BIOX income_statement (quarterly, 2025-12-31) — Operating Revenue: 73674526.00
BIOX balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 63815891.00
BIOX cash_flow (quarterly, 2025-12-31) — Other Cash Adjustment Outside Changein Cash: -555859.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 90063228.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 28154843.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: 30749501.00
BIOX income_statement (quarterly, 2025-12-31) — Other Gand A: 3631533.00
BIOX income_statement (quarterly, 2025-12-31) — Other Income Expense: -1240453.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 87289801.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Inventories: 2363568.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Investments: 49.00
BIOX cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 8555094.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 372373.00
BIOX income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 26410.00
BIOX income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 88420.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Payable: 218877.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Properties: 23581646.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Receivables: 1223677.00
BIOX balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 1515145.00
BIOX income_statement (quarterly, 2025-12-31) — Other Taxes: 2461168.00
BIOX balance_sheet (quarterly, 2025-12-31) — Payables: 95837127.00
BIOX balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 95837127.00
BIOX balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 4964421.00
BIOX balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 6341644.00
BIOX income_statement (quarterly, 2025-12-31) — Pretax Income: -1366138.00
BIOX balance_sheet (quarterly, 2025-12-31) — Properties: 34596981.00
BIOX cash_flow (quarterly, 2025-12-31) — Provisionand Write Offof Assets: 1170646.00
BIOX cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: -2403.00
BIOX cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -719608.00
BIOX cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: 12473.00
BIOX balance_sheet (quarterly, 2025-12-31) — Raw Materials: 16583712.00
BIOX balance_sheet (quarterly, 2025-12-31) — Receivables: 165841906.00
BIOX income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 47138711.00
BIOX income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 1185705.00
BIOX cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -18507567.00
BIOX income_statement (quarterly, 2025-12-31) — Research And Development: 2347566.00
BIOX balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -255411089.00
BIOX income_statement (quarterly, 2025-12-31) — Salaries And Wages: 5742103.00
BIOX cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 181499.00
BIOX cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 26504.00
BIOX income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 2889197.00
BIOX income_statement (quarterly, 2025-12-31) — Selling General And Administration: 12628409.00
BIOX balance_sheet (quarterly, 2025-12-31) — Share Issued: 65881505.00
BIOX income_statement (quarterly, 2025-12-31) — Special Income Charges: -400818.00
BIOX cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: -533.00
BIOX balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 73770442.00
BIOX balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -49593042.00
BIOX income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -468690.95
BIOX income_statement (quarterly, 2025-12-31) — Tax Provision: 3109370.00
BIOX income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.35
BIOX balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 9406852.00
BIOX balance_sheet (quarterly, 2025-12-31) — Total Assets: 560361541.00
BIOX balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 107926405.00
BIOX balance_sheet (quarterly, 2025-12-31) — Total Debt: 239456462.00
BIOX balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 106616301.00
BIOX income_statement (quarterly, 2025-12-31) — Total Expenses: 65849979.00
BIOX balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 453745240.00
BIOX balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 266081487.00
BIOX balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 125108436.00
BIOX income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 7522393.00
BIOX income_statement (quarterly, 2025-12-31) — Total Other Finance Cost: 929269.00
BIOX balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 12275955.00
BIOX income_statement (quarterly, 2025-12-31) — Total Unusual Items: -1339117.00
BIOX income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -1339117.00
BIOX balance_sheet (quarterly, 2025-12-31) — Tradeand Other Payables Non Current: 51650942.00
BIOX balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 2065614.00
BIOX balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 25170263.00
BIOX balance_sheet (quarterly, 2025-12-31) — Working Capital: -34356750.00
BIOX income_statement (quarterly, 2025-12-31) — Write Off: 427322.00
BIOX income_statement (quarterly, 2026-03-31) — +Operating Expense: 17500000.00
BIOX income_statement (quarterly, 2026-03-31) — +Total Revenue: 38200000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 79600000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 136300000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 42400000.00
BIOX income_statement (quarterly, 2026-03-31) — Basic Average Shares: 63600000.00
BIOX income_statement (quarterly, 2026-03-31) — Basic EPS: -0.14
BIOX balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 11200000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 14400000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 14900000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 67700000.00
BIOX income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 25500000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Current Assets: 260700000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 2600000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Current Debt: 174700000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 177300000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 2800000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 2800000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 297500000.00
BIOX income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 63600000.00
BIOX income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.14
BIOX income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -9000000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Dueto Related Parties Non Current: 700000.00
BIOX income_statement (quarterly, 2026-03-31) — EBIT: -7500000.00
BIOX income_statement (quarterly, 2026-03-31) — EBITDA: -7500000.00
BIOX income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest: 500000.00
BIOX income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -1800000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Goodwill: 36100000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 120000000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Gross PPE: 71400000.00
BIOX income_statement (quarterly, 2026-03-31) — Gross Profit: 12700000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Income Tax Payable: 4800000.00
BIOX income_statement (quarterly, 2026-03-31) — Interest Expense: 6600000.00
BIOX income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 6600000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Inventory: 52800000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Invested Capital: 296500000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Investment Properties: 0.00
BIOX balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 0.00
BIOX balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 41300000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 8600000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 54100000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 62700000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 41300000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 1000000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Minority Interest: 27900000.00
BIOX income_statement (quarterly, 2026-03-31) — Minority Interests: 1100000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Net Debt: 214400000.00
BIOX income_statement (quarterly, 2026-03-31) — Net Income: -9000000.00
BIOX income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -9000000.00
BIOX income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -10100000.00
BIOX income_statement (quarterly, 2026-03-31) — Net Income Discontinuous Operations: 0.00
BIOX income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -9000000.00
BIOX income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -9000000.00
BIOX income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -10000000.00
BIOX income_statement (quarterly, 2026-03-31) — Net Interest Income: -7900000.00
BIOX income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -7900000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Net PPE: 71400000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -52300000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Non Current Accounts Receivable: 30500000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 6500000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 25700000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 1400000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 6500000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 24300000.00
BIOX income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -5700000.00
BIOX income_statement (quarterly, 2026-03-31) — Normalized Income: -7710638.30
BIOX income_statement (quarterly, 2026-03-31) — Operating Income: -4800000.00
BIOX income_statement (quarterly, 2026-03-31) — Operating Revenue: 38200000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 63815891.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Current Assets: -100000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 174700000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 29400000.00
BIOX income_statement (quarterly, 2026-03-31) — Other Income Expense: -1300000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 83900000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Inventories: 52800000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: -800000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 200000.00
BIOX income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 17500000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Properties: 71400000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Receivables: 13000000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 500000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Payables: 84400000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 84400000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 3600000.00
BIOX income_statement (quarterly, 2026-03-31) — Pretax Income: -14100000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Receivables: 150700000.00
BIOX income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 25500000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Share Issued: 63815891.00
BIOX balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 67700000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -52300000.00
BIOX income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -510638.30
BIOX income_statement (quarterly, 2026-03-31) — Tax Provision: -4000000.00
BIOX income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.28
BIOX balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 1400000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Total Assets: 529600000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 121800000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Total Debt: 240000000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 95600000.00
BIOX income_statement (quarterly, 2026-03-31) — Total Expenses: 43000000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 434000000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 268900000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 136500000.00
BIOX income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -4300000.00
BIOX income_statement (quarterly, 2026-03-31) — Total Other Finance Cost: 1300000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 4800000.00
BIOX income_statement (quarterly, 2026-03-31) — Total Unusual Items: -1800000.00
BIOX income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -1800000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 46200000.00
BIOX balance_sheet (quarterly, 2026-03-31) — Working Capital: -36800000.00
BIP cash_flow (annual, 2021-12-31) — Common Stock Issuance: 1073000000.00
BIP cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 1073000000.00
BIP balance_sheet (annual, 2021-12-31) — Prepaid Assets: 328000000.00
BIP cash_flow (annual, 2021-12-31) — Short Term Debt Issuance: 6359000000.00
BIP cash_flow (annual, 2021-12-31) — Short Term Debt Payments: -7059000000.00
BIP income_statement (annual, 2022-12-31) — +Operating Expense: 433000000.00
BIP income_statement (annual, 2022-12-31) — +Total Revenue: 14427000000.00
BIP balance_sheet (annual, 2022-12-31) — Accounts Payable: 1872000000.00
BIP balance_sheet (annual, 2022-12-31) — Accounts Receivable: 2276000000.00
BIP balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -5396000000.00
BIP cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 561000000.00
BIP cash_flow (annual, 2022-12-31) — Amortization Of Intangibles: 561000000.00
BIP balance_sheet (annual, 2022-12-31) — Assets Held For Sale Current: 856000000.00
BIP balance_sheet (annual, 2022-12-31) — Available For Sale Securities: 473000000.00
BIP income_statement (annual, 2022-12-31) — Basic Average Shares: 458100000.00
BIP income_statement (annual, 2022-12-31) — Basic EPS: 0.14
BIP cash_flow (annual, 2022-12-31) — Beginning Cash Position: 1406000000.00
BIP cash_flow (annual, 2022-12-31) — Capital Expenditure: -2775000000.00
BIP balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 3421000000.00
BIP balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 1138000000.00
BIP balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 2266000000.00
BIP cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -1418000000.00
BIP balance_sheet (annual, 2022-12-31) — Cash Equivalents: 454000000.00
BIP balance_sheet (annual, 2022-12-31) — Cash Financial: 684000000.00
BIP cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 56000000.00
BIP cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -3365000000.00
BIP cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 3131000000.00
BIP cash_flow (annual, 2022-12-31) — Change In Account Payable: -342000000.00
BIP cash_flow (annual, 2022-12-31) — Change In Payable: -342000000.00
BIP cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -342000000.00
BIP cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -117000000.00
BIP cash_flow (annual, 2022-12-31) — Change In Receivables: -445000000.00
BIP cash_flow (annual, 2022-12-31) — Change In Working Capital: -904000000.00
BIP cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -445000000.00
BIP cash_flow (annual, 2022-12-31) — Changes In Cash: -178000000.00
BIP balance_sheet (annual, 2022-12-31) — Commercial Paper: 464000000.00
BIP cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: -1418000000.00
BIP balance_sheet (annual, 2022-12-31) — Common Stock Equity: 6317000000.00
BIP cash_flow (annual, 2022-12-31) — Common Stock Issuance: 13000000.00
BIP cash_flow (annual, 2022-12-31) — Common Stock Payments: -243000000.00
BIP income_statement (annual, 2022-12-31) — Cost Of Revenue: 10510000000.00
BIP balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 1395000000.00
BIP balance_sheet (annual, 2022-12-31) — Current Assets: 6686000000.00
BIP balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 384000000.00
BIP balance_sheet (annual, 2022-12-31) — Current Debt: 3178000000.00